Comparative Efficacy and Mechanism of Trulicity and Zepbound

Introduction to Medications

• Trulicity (dulaglutide) is a selective GLP-1 receptor agonist, while Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist, representing a fundamental difference in their mechanism of action 1, 2

Pharmacological Mechanism

• Dulaglutide acts solely on GLP-1 receptors, stimulating insulin secretion and reducing glucagon secretion in a glucose-dependent manner 3, 4
• Tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, though its affinity for the GLP-1 receptor is approximately five times less than endogenous GLP-1 1, 2

Comparative Efficacy

• Tirzepatide produces significantly greater reductions in HbA1c and body weight compared with dulaglutide 1, 2, 5

GIP Receptor Effects

• GIP receptor activation augments glucagon secretion during euglycemia/hypoglycemia but inhibits it during hyperglycemia 1, 2
• GIP receptors are expressed on pancreatic alpha cells, while only 10-15% of alpha cells express GLP-1 receptors 1, 2

Pharmacokinetic Differences

• Both medications are long-acting formulations administered once weekly, but achieve prolonged action through different molecular modifications 1, 2
• Dulaglutide achieves prolonged elimination from conjugation with the fragment crystallizable region of immunoglobulin G 1, 2, 5
• Tirzepatide is modified to prevent dipeptidyl peptidase-4 cleavage with dual receptor binding properties 1, 2

Clinical Positioning

• For patients requiring maximal glycemic control and weight loss, tirzepatide represents the superior choice based on direct comparative evidence 1, 2
• Both medications share minimal hypoglycemia risk when used as monotherapy 3, 4
• Dulaglutide has established cardiovascular outcome data showing MACE reduction 6, 7
• Both medications are contraindicated in patients at risk for thyroid C-cell tumors 6, 7